Antistaphylococcal immunoglobulins to prevent staphylococcal infection in very low birth weight infants

Anti-lipoteichoic acid monoclonal antibody (pagibaximab) studies for the prevention of staphylococcal bloodstream infections in preterm infants

“…From this and other neonatal studies, we know that alone the antibody preparations examined in the preterm infant have not been successful in preventing late-onset infection [2][3][4]. Antibodies depend on other factors including complement, for example, which is also deficient in preterm infants.…”

“…been studied [2][3][4][5]. A 2009 Cochrane review evaluated the effects of two antistaphylococcal immunoglobulins, Altastaph and INH A-2, on prevention of late-onset sepsis in VLBW infants £ 32 weeks [2].…”

“…A 2009 Cochrane review evaluated the effects of two antistaphylococcal immunoglobulins, Altastaph and INH A-2, on prevention of late-onset sepsis in VLBW infants £ 32 weeks [2]. The review concluded there was no significant reduction in the risk of infection or mortality when used for the prevention of staphylococcal infections in VLBW infants.…”

Anti-lipoteichoic acid monoclonal antibody (pagibaximab) studies for the prevention of staphylococcal bloodstream infections in preterm infants

“…From this and other neonatal studies, we know that alone the antibody preparations examined in the preterm infant have not been successful in preventing late-onset infection [2][3][4]. Antibodies depend on other factors including complement, for example, which is also deficient in preterm infants.…”

“…been studied [2][3][4][5]. A 2009 Cochrane review evaluated the effects of two antistaphylococcal immunoglobulins, Altastaph and INH A-2, on prevention of late-onset sepsis in VLBW infants £ 32 weeks [2].…”

“…A 2009 Cochrane review evaluated the effects of two antistaphylococcal immunoglobulins, Altastaph and INH A-2, on prevention of late-onset sepsis in VLBW infants £ 32 weeks [2]. The review concluded there was no significant reduction in the risk of infection or mortality when used for the prevention of staphylococcal infections in VLBW infants.…”

Prevention and treatment of neonatal nosocomial infections

“…Since Staphylococci, especially CONS, are responsible for the majority of late-onset infections in VLBW infants, IVIG preparations containing various type specific antibodies targeting different antigenic sites were developed, but studies of these products (Veronate or INH-A21: antibody against microbial surface components recognizing adhesive matrix molecules, Altastaph: antibody against capsular polysaccharide antigen type 5 and 8, and Pagibaximab: anti-lipoteichoic human chimeric monoclonal antibody) have also shown disappointing results [ 59 , 60 ]. IgM-enriched immunoglobulins are being evaluated as adjuvant therapy for VLBW infants with proven sepsis, but not for prophylaxis [ 61 ].…”

Physiology and Abnormalities of Leukocytes in Newborns

“…Shah and Kaufman conducted a systematic review to evaluate the efficacy and safety of antistaphylococcal immunoglobulins in the prevention of Staphylococcal infection in very low birth weight infants (Shah and Kaufman 2009). Three eligible studies were included testing two different antistaphylococcal immunoglobulin products.…”

Anti-lipoteichoic acid monoclonal antibody (pagibaximab) studies for the prevention of staphylococcal bloodstream infections in preterm infants

“…From this and other neonatal studies, we know that alone the antibody preparations examined in the preterm infant have not been successful in preventing late-onset infection [2][3][4]. Antibodies depend on other factors including complement, for example, which is also deficient in preterm infants.…”

“…been studied [2][3][4][5]. A 2009 Cochrane review evaluated the effects of two antistaphylococcal immunoglobulins, Altastaph and INH A-2, on prevention of late-onset sepsis in VLBW infants £ 32 weeks [2].…”

“…A 2009 Cochrane review evaluated the effects of two antistaphylococcal immunoglobulins, Altastaph and INH A-2, on prevention of late-onset sepsis in VLBW infants £ 32 weeks [2]. The review concluded there was no significant reduction in the risk of infection or mortality when used for the prevention of staphylococcal infections in VLBW infants.…”

Prevention and treatment of neonatal nosocomial infections

“…Since Staphylococci, especially CONS, are responsible for the majority of late-onset infections in VLBW infants, IVIG preparations containing various type specific antibodies targeting different antigenic sites were developed, but studies of these products (Veronate or INH-A21: antibody against microbial surface components recognizing adhesive matrix molecules, Altastaph: antibody against capsular polysaccharide antigen type 5 and 8, and Pagibaximab: anti-lipoteichoic human chimeric monoclonal antibody) have also shown disappointing results [ 59 , 60 ]. IgM-enriched immunoglobulins are being evaluated as adjuvant therapy for VLBW infants with proven sepsis, but not for prophylaxis [ 61 ].…”

Physiology and Abnormalities of Leukocytes in Newborns

“…Shah and Kaufman conducted a systematic review to evaluate the efficacy and safety of antistaphylococcal immunoglobulins in the prevention of Staphylococcal infection in very low birth weight infants (Shah and Kaufman 2009). Three eligible studies were included testing two different antistaphylococcal immunoglobulin products.…”

Anti-lipoteichoic acid monoclonal antibody (pagibaximab) studies for the prevention of staphylococcal bloodstream infections in preterm infants

“…From this and other neonatal studies, we know that alone the antibody preparations examined in the preterm infant have not been successful in preventing late-onset infection [2][3][4]. Antibodies depend on other factors including complement, for example, which is also deficient in preterm infants.…”

“…been studied [2][3][4][5]. A 2009 Cochrane review evaluated the effects of two antistaphylococcal immunoglobulins, Altastaph and INH A-2, on prevention of late-onset sepsis in VLBW infants £ 32 weeks [2].…”

“…A 2009 Cochrane review evaluated the effects of two antistaphylococcal immunoglobulins, Altastaph and INH A-2, on prevention of late-onset sepsis in VLBW infants £ 32 weeks [2]. The review concluded there was no significant reduction in the risk of infection or mortality when used for the prevention of staphylococcal infections in VLBW infants.…”

Prevention and treatment of neonatal nosocomial infections

“…Since Staphylococci, especially CONS, are responsible for the majority of late-onset infections in VLBW infants, IVIG preparations containing various type specific antibodies targeting different antigenic sites were developed, but studies of these products (Veronate or INH-A21: antibody against microbial surface components recognizing adhesive matrix molecules, Altastaph: antibody against capsular polysaccharide antigen type 5 and 8, and Pagibaximab: anti-lipoteichoic human chimeric monoclonal antibody) have also shown disappointing results [ 59 , 60 ]. IgM-enriched immunoglobulins are being evaluated as adjuvant therapy for VLBW infants with proven sepsis, but not for prophylaxis [ 61 ].…”

Physiology and Abnormalities of Leukocytes in Newborns

“…Shah and Kaufman conducted a systematic review to evaluate the efficacy and safety of antistaphylococcal immunoglobulins in the prevention of Staphylococcal infection in very low birth weight infants (Shah and Kaufman 2009). Three eligible studies were included testing two different antistaphylococcal immunoglobulin products.…”